Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Protocol Title: Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-003 Delivered by Intravenous Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. Protocol Name: ASCENT-1: Activated, Selective, Controlled Expression of a Novel Programmable mRNA Therapeutic

Trial Details

NCT ID
NCT07751042
Phase
PHASE1 / PHASE2
Sponsor
Strand Therapeutics Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • STX-003
  • KEYTRUDA®
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Wollstonecraft, New South Wales, Australia|-33.8328,151.18981

Key Eligibility Criteria

  • Inclusion Criteria (Phase 1 and Phase 2)
  • Mentally competent and able to understand and sign the ICF.
  • Tumor type for which there is an FDA-approved anti-PD-1/L1 antibody therapy, specifically including biomarker labeled subsets (i.e. PD-L1+) as well…
  • Histologically or cytologically documented, locally advanced, or metastatic solid tumor.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →